Business
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million
PARIS, November 10, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/9e9ec8217cc814fa00c59544dae7004e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NlNm2bJ9EcKypS3FeegAzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9e9ec8217cc814fa00c59544dae7004e","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, November 10, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 1,999,998.1515 fundraising subscribed by two investors which were existing shareholders: Invus and Alumni Capital (the "Fundraising"). This fundraising follows the EUR 4.5 million private placement completed in July (in two tranches) and the EUR 3.7 million fundraising completed in early October. The Fundraising uses the same structure of shares and warrants, including pre-funded warrants, as detailed further below.","length":771,"tagName":"p"},{"type":"text","content":""Our strategy to move the development of GS010/LUMEVOQ forward has continued to progress, with a first regulatory milestone achieved recently with the FDA," said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "The momentum has further strengthened our shareholders' confidence, as shown by this recent infusion of investment. We are grateful for their continued support as we advance toward our goal of bringing this innovative gene therapy to patients suffering from Leber Hereditary Optic Neuropathy."","length":547,"tagName":"p"},{"type":"text","content":"The Fundraising is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des march...